Drug‐Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches—A Narrative Review
Authors:
- Hashim Mohamed SirajHSHashim Mohamed Siraj
- Masab AliMAMasab Ali
- Sampda Sanjaykumar SharmaSSSampda Sanjaykumar Sharma
- Afreen BegumABAfreen Begum
- Muhammad Husnain AhmadMAMuhammad Husnain Ahmad
- Muhammad HassanMHMuhammad Hassan
- Roba Kamaleldin Moustafa Kamel Aref ElsayedRERoba Kamaleldin Moustafa Kamel Aref Elsayed
- Muhammad Hamza TahirMTMuhammad Hamza Tahir
Open Access
- 16 April 2025
- journal article
- Published by Wiley in Health Science Reports
- Vol. 8 (4) , e70667
Abstract
Background and Aims: Drug‐induced renal vasculitis arises from various medications that cause immunological dysregulation or direct vascular damage, leading to inflammation and thrombosis. Clinical manifestations vary widely, from mild constitutional symptoms to severe organ dysfunction. This review aims to thoroughly explore drug‐induced renal vasculitis, focusing on its etiology, pathological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic approaches. This review aims to summarize current knowledge and highlight areas requiring further research.Methods: A comprehensive literature search was conducted using PubMed, MEDLINE, Embase, and Cochrane Library databases. We included peer‐reviewed journal articles and excluded those with insufficient data, poor quality, or lack of relevance. The search terms included combinations of “renal vasculitis,” “drug‐induced vasculitis,” “drug‐related nephritis,” “medication‐induced renal vasculitis,” and specific drug names. An initial search yielded 13,192 articles, of which 13,103 were excluded due to irrelevance, duplication, or outdated information. After full‐text review, 99 peer‐reviewed articles were included.Results: Discontinuation of the offending drug is the primary and most crucial step in managing drug‐induced renal vasculitis. Prognosis is generally more favorable than primary vasculitis, with a high remission rate if the offending drug is stopped early. Due to its rarity, epidemiological data is limited. Diagnosis frequently relies on autoantibodies [antineutrophil cytoplasm antibodies (ANCA), myeloperoxidase (MPO), antinuclear antibody (ANA)] and clinical symptoms, with renal biopsy confirming it. Factors such as high‐dose and long‐term drug use, as well as genetic predispositions, increase the risk.Conclusion: This review provides a comprehensive overview of drug‐induced renal vasculitis, discussing what is known and identifying gaps in understanding. While discontinuing the causative drug remains the cornerstone of management, further research is needed, particularly in developing a formal tool to assess the quality of studies and minimize selection bias.Keywords
This publication has 103 references indexed in Scilit:
- Renal vasculitis associated with ciprofloxacinAmerican Journal of Kidney Diseases, 1995
- Autoantibodies to leucocyte antigens in hydralazine‐associated nephritisJournal of Internal Medicine, 1992
- Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatmentJournal of Internal Medicine, 1991
- Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.Journal of Clinical Investigation, 1990
- Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structureBiochemical Pharmacology, 1988
- Natural course of penicillamine nephropathy: a long term study of 33 patientsBMJ, 1988
- The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortalityArthritis & Rheumatism, 1986
- Novel assay and pharmacokinetics of levamisole and p‐hydroxylevamisole in human plasma and urineBiopharmaceutics & Drug Disposition, 1986
- Antithyroid DrugsNew England Journal of Medicine, 1984
- Necrotizing vasculitis associated with diphenylhydantoin: Two fatal casesHuman Pathology, 1983